Naloxone is the opioid overdose reversal medication, and its widespread community availability is one of the most consequential public health interventions of the past decade. The mechanism is straightforward: competitive mu opioid receptor antagonism. Naloxone displaces opioids from receptors and reverses respiratory depression within 2-5 minutes after IM or intranasal administration.
- Class
- Pure opioid receptor antagonist
- Mechanism
- Competitive mu opioid receptor antagonist — displaces opioids from receptors, reverses respiratory depression and sedation
- Typical dose
- Intranasal 4 mg (Narcan) or 8 mg (Kloxxado) per dose; IM/SC 0.4 mg per dose; IV 0.04-0.4 mg titrated
- Half-life
- ~60-90 minutes (shorter than most opioids — re-overdose possible)
- FDA indications
- Suspected opioid overdose (respiratory depression, severe sedation)
- Key adverse effects
- Precipitated opioid withdrawal in opioid-dependent patients (uncomfortable but not life-threatening), possible recurrence of overdose as naloxone wears off
Intranasal Narcan now over-the-counter in US — community distribution essential for overdose prevention. Every patient with OUD and their household should have access. Multiple doses may be needed for fentanyl/synthetic opioids. Re-dose every 2-3 minutes if no response; call EMS regardless.
Intranasal Narcan is now over-the-counter in the United States. No prescription required. Available at pharmacies, distributed at community programs, increasingly carried by first responders, family members, and friends. The OTC availability has transformed who can administer overdose reversal — moving from medical personnel only to anyone who witnesses an overdose.
Every patient with opioid use disorder, every patient on chronic opioid therapy, and every household member of such patients should have access. Education at every OUD visit. The patient on naltrexone or buprenorphine still benefits from naloxone availability — relapse can be fatal and unexpected.
- Cost
- Intranasal Narcan OTC ~$45-50/dose (2-pack). Generic less. Some state programs distribute free.
- Generic status
- OTC since 2023.
- Formulary typical
- Many plans cover with co-pay. State programs often distribute free.
- Access friction
- OTC removed prescription barrier. Some states have additional programs (vending machines in some areas).
Prescriber tip: Every patient with OUD should have naloxone. Many state programs (state.naloxone.org or similar) distribute free. Counsel household members on use.
For administration: recognize signs of overdose (unresponsive, slow or absent breathing, pinpoint pupils), call 911, administer naloxone, support breathing with rescue breaths or BVM if available. Re-dose every 2-3 minutes if no response.
Naloxone is the opioid overdose reversal agent — a fast, competitive antagonist that displaces opioids from the receptor.
Mechanism note: Naloxone reverses opioid overdose fast — but its short duration means re-dosing and observation are essential, and broad community distribution is core harm-reduction practice.
Fentanyl-era considerations. Synthetic opioids like fentanyl have substantially higher potency than heroin. Naloxone still works, but multiple doses are often needed. The standard counseling now: if no response to the first dose, give a second. If still no response, give a third. Don't wait for EMS to arrive before continuing administration.
Naloxone's half-life is shorter than most opioids it reverses — 30-90 minutes. After successful reversal, opioids may re-distribute from tissues and the patient can re-overdose as naloxone wears off. EMS evaluation and observation are essential after every reversal, even when the patient appears stable. Discharging too early after reversal is a serious clinical error.
Naloxone causes withdrawal in opioid-dependent patients. The reversal is unpleasant — the patient often experiences acute withdrawal. That's a tolerable cost for survival.